ADHD drug SPN-812 tested for Long-Term safety in children

NCT ID NCT02736656

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study investigates the long-term safety and effectiveness of SPN-812 (viloxazine) in children and adolescents with ADHD. Participants who completed a prior SPN-812 study can continue taking the medication once daily for up to 72 months. The trial includes children aged 4–17 years and monitors side effects and symptom changes over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
viloxazine extended-release capsules (SPN-812)
What this could lead to
If successful, this could confirm viloxazine as a safe long-term treatment option for managing ADHD symptoms in children and adolescents.
What could go wrong
This is an open-label extension study without a placebo group, so results may be less reliable. Long-term side effects are still being monitored.
Why investors are watching

Supernus Pharmaceuticals is running a Phase 3 open-label extension study of SPN-812, its ADHD drug for children, in 1,400 patients. This trial tests long-term safety and efficacy, which matters because regulators and doctors need years of data before the drug can become a standard treatment. For a small company, this readout can determine whether SPN-812 becomes a reliable revenue source or remains an unproven product.

If it works: If the trial shows the drug stays safe and effective over the long term, Supernus could gain a stronger position in the pediatric ADHD market. That result might support regulatory approval and encourage wider use, which would help the company grow.

If it fails: If the trial reveals safety problems or weak long-term efficacy, the drug's future could be in doubt. Clinical trials often fail, and a negative result here could hurt the company's prospects and delay any potential approval.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2016

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Cohort 'A' Inclusion/Exclusion Criteria: Inclusion Criteria 'A': 1. Completion of a previous blinded study of SPN-812 for the treatment of ADHD. 2. Continues to be medically healthy and with clinically normal laboratory profiles, vital signs, and electrocardiograms (ECGs). 3. Weight of at least 20 kg if 6-11 years old and at least 35 kg if 12 years or older. 4. Written Informed Consent obtained from the subject's parent or legally authorized representative (LAR); and written Informed Assent obtained from the subject if appropriate; written Informed Consent obtained from the subject if he/she is 18 years old. 5. Females of Childbearing Potential (FOCP) must be either sexually inactive (abstinent) or, if sexually active, must agree to use one of the following acceptable birth control methods beginning 30 days prior to the first dose, throughout the study: 1. simultaneous use of male condom and intra-uterine contraceptive device placed at least four weeks prior to the first study drug administration 2. surgically sterile male partner 3. simultaneous use of male condom and diaphragm with spermicide 4. established hormonal contraceptive Exclusion Criteria 'A': 1. Current diagnosis of significant systemic disease or of a major psychiatric or neurological disorder, including history or family history of seizures or seizure-like disorders. History of Major Depressive Disorder is allowed if the subject is free of episodes currently and for the last six months. 2. Current evidence of suicidal ideation and/or behaviors (assessed with Columbia Suicide Severity Rating Scale or C-SSRS). 3. Body Mass Index (BMI) greater than 95th percentile for the appropriate age and gender (according to the CDC BMI-for-Age Growth Charts for boys and girls). 4. Pregnancy, breastfeeding, or refusal to practice contraception during the study for female subjects of childbearing potential (FOCP). 5. Current substance or alcohol use. 6. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study. Cohort 'B' Inclusion/Exclusion Criteria: Inclusion Criteria 'B': 1. Has completed a previous Study 812P401 and is less than 6 years of age at Visit 1 in this study (812P310). 2. Continues to be medically healthy with clinically normal laboratory profiles, vital signs, and electrocardiograms. 3. Weighs at least ≥5th percentile for age and sex. 4. Parent or LAR is willing and able to provide Written Informed Consent. Exclusion Criteria 'B': 1. Has a current diagnosis of significant systemic disease and/or of a major psychiatric or neurological disorder. 2. Current evidence of suicidal ideation and/or behaviors (assessed with Columbia Suicide Severity Rating Scale or C-SSRS), is at significant risk of suicide, either in the opinion of the Investigator or defined as a "yes" to suicidal ideation C-SSRS questions 4 or 5 or answering "yes" to suicidal behavior on the C-SSRS at Visit 1 or has attempted suicide from day of end of study in previous blinded study to day of Visit 1 in this study (812P310). 3. Has a BMI \>95th percentile for the appropriate age and sex (according to the CDC BMI-for-Age Growth Charts for boys and girls). 4. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention deficit hyperactivity disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Alliance for Wellness dba Alliance for Research

    Long Beach, California, 90807, United States

  • Bayou City Research Corporation

    Houston, Texas, 77006, United States

  • CNS Healthcare

    Memphis, Tennessee, 38119, United States

  • Clinical Neuroscience Solutions, Inc.

    Memphis, Tennessee, 38119, United States

  • Ericksen Research & Development

    Clinton, Utah, 84015, United States

  • Florida Clinical Research Center, LLC

    Maitland, Florida, 32751, United States

  • Florida Clinical Research Center, LLC.

    Maitland, Florida, 32751, United States

  • IPS Research

    Oklahoma City, Oklahoma, 73103, United States

  • Indago Research & Health Center, Inc.

    Hialeah, Florida, 33012, United States

  • MCB Clinical Research Centers, LLC

    Colorado Springs, Colorado, 80910, United States

  • Meridien Research at Florida Clinical Research Center

    Bradenton, Florida, 34201, United States

  • Northwest Clinical Trials

    Bellevue, Washington, 98004, United States

  • Paradigm Research Professionals

    Oklahoma City, Oklahoma, 73118, United States

  • Road Runner Research

    San Antonio, Texas, 78258, United States

  • Sarkis Clinical Trials

    Gainesville, Florida, 32607, United States

  • Woodland International Research Group

    Little Rock, Arkansas, 72211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.